RxDoctor Payments Data

Yan Qi, MD

Neurology · North Wales, PANPI 1982683090

Payments from drug & device makers

$1,435in general payments, 2019–2025

Across 81 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$251
  • Teva Pharmaceuticals USA, Inc.$236
  • Sanofi$200
  • Supernus Pharmaceuticals, Inc.$197
  • Amgen$158
  • AbbVie$154
  • plus $239 from 10 others

What the payments were for

  • Consulting fees$15010%
  • Speaking & faculty fees$22416%
  • Food & beverage$95066%
  • Education$1118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,435 in reported general payments places this provider in the 50th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$196,160
Medicare patients
620
Services billed
2,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$257,073
CopaxoneGlatiramer Acetate29$178,029
Dimethyl Fumarate35$52,028
Emgality PenGalcanezumab-Gnlm19$13,255
QuliptaAtogepant11$11,895
Carbidopa-LevodopaCarbidopa/Levodopa322$8,966
Aimovig AutoinjectorErenumab-Aooe12$8,825
Memantine Hcl254$8,693
Gabapentin330$7,010
Levetiracetam171$4,954
Donepezil Hcl442$4,854
Pregabalin192$3,448
Lacosamide27$2,958
DilantinPhenytoin Sodium Extended11$2,632
Carbamazepine ErCarbamazepine21$2,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$15$257,07313 claims
Teva Pharmaceuticals USA, Inc.Copaxone$236$178,02929 claims
AbbVieQulipta$154$11,89511 claims
PfizerDilantin$14$2,63211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 941 neurology providers in Pennsylvania.

Other neurology in North Wales

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →